Cancer Survival Rates Lower in Midwest Than Rest of Ireland
Midwest Lags Behind in Cancer Survival Rates, New Report Finds
A new report from the National Cancer registry Ireland (NCRI) reveals concerning disparities in cancer survival rates across the country, with the Midwest region showing significantly lower five-year survival rates for several common cancers.
The report, which analyzed data from 2009 to 2018, found that patients diagnosed with lung, colorectal, breast, and prostate cancer in the Midwest had lower chances of surviving at least five years compared to the national average and other regions.
For lung cancer,the Midwest’s five-year net survival rate was a stark 16.1%,compared to the national average of 20.8%. Similarly, colorectal cancer survival in the Midwest stood at 59.4%,falling short of the national rate of 63.5%.
While breast and prostate cancer survival rates in the Midwest where higher, they still lagged behind the national average. Breast cancer survival was 80.1% in the Midwest compared to 85.1% nationally, and prostate cancer survival was 90.4% in the Midwest versus 92.5% nationally.
the report’s authors note that the period analyzed coincided with the centralization of cancer services in Ireland, which may have impacted regional variations in care.
Regional Disparities in Cancer Incidence
The report also highlighted regional differences in cancer incidence. While the three eastern regions (Dublin and Northeast, Dublin and Midlands, and Dublin and Southeast) accounted for 60% of all invasive cancers diagnosed between 2020 and 2022, reflecting their larger populations, some specific cancer types showed variations.
Dublin and Midlands had a higher overall cancer incidence rate (596 per 100,000) compared to the national average, while Dublin and Northeast had a lower rate (560 per 100,000).
Call for Targeted Investments in Cancer Care
“While geographic variation must always be interpreted with care, these data can point to crucial opportunities for improvement across cancer care,” said Prof. Murray, emphasizing the need for targeted investments in prevention, early diagnosis, screening, and access to treatment.
The report also underscored the ongoing impact of the COVID-19 pandemic on cancer diagnoses,with a shortfall of 2% in 2022,a significant improvement from the 10% shortfall seen in 2020.
Dr. Robert O’Connor, chair of the NCRI board, stressed the importance of the report’s findings, stating, “The data reveal critical insights into regional health outcome differences and emerging trends in cancer survival rates. The findings underscore the continued need for targeted, strategic investments in cancer research, prevention, treatment, and post-treatment care to equitably maximize patient outcomes and community health.”
Midwest Falls Behind National Averages in Cancer Survival Rates, New Report Reveals
Dublin, Ireland – A new report from the National Cancer Registry Ireland (NCRI) has uncovered concerning disparities in cancer survival rates across the country. The Midwest region is lagging behind the national average in several common cancers, prompting calls for targeted investments to improve cancer care in the area.
The report, analyzing data from 2009 to 2018, found significantly lower five-year survival rates for lung, colorectal, breast, and prostate cancer in the Midwest compared to the national average and other regions.
Lung cancer survival in the Midwest stood at a worrying 16.1%, compared to the national average of 20.8%. Colorectal cancer survival in the region was 59.4%, falling short of the national rate of 63.5%. While breast and prostate cancer survival in the Midwest were higher, they remained below the national average at 80.1% and 90.4% respectively, compared to 85.1% and 92.5% nationally.
Professor Ciaran Murray, highlighting the need for targeted investments in prevention, early diagnosis, screening, and access to treatment, stated, “While geographic variation must always be interpreted with care, these data can point to crucial opportunities for improvement across cancer care.”
The report also revealed regional discrepancies in cancer incidence. The three eastern regions (Dublin and Northeast, Dublin and Midlands, and Dublin and Southeast) accounted for 60% of all invasive cancers diagnosed between 2020 and 2022, likely reflecting their larger populations. Though, specific cancer types showed varying incidence rates across these regions. dublin and Midlands, such as, had a higher overall cancer incidence rate compared to the national average.
Dr. Robert O’Connor, chair of the NCRI board, emphasized the report’s findings, saying, “The data reveal critical insights into regional health outcome differences and emerging trends in cancer survival rates. The findings underscore the continued need for targeted, strategic investments in cancer research, prevention, treatment, and post-treatment care to equitably maximize patient outcomes and community health.”
The report also acknowledged the ongoing impact of the COVID-19 pandemic on cancer diagnoses, noting a 2% shortfall in 2022, a notable improvement from the 10% shortfall observed in 2020.